Top Markets
Coin of the day
Neovacs S.A. Neovacs S.A.

Neovacs S.A.

ALNEV
株式のランク #21228
Neovacs S.A., a biotechnology company, focuses on the development of... Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.
株価
$0.00047446
時価総額
$82.80
変化(1日)
0.00%
変化(1年)
-98.16%
FR
取引 Neovacs S.A. (ALNEV)

カテゴリー

Neovacs S.A.(ALNEV)の営業利益率
April 2026 時点の営業利益率 TTM: -1,846.44%
Neovacs S.A. の最新の財務報告と株価によると、現在の営業利益率(TTM)は -1,846.44% です。2023 年末時点では -1,294.97% でした。
Neovacs S.A. の営業利益率の履歴(2007 から 2026)
各年末の営業利益率
営業利益率 変化
2026 (TTM) -1,846.44% 0.00%
2024 -1,846.44% 42.59%
2023 -1,294.97% -99.78%
2022 -579,583.27% 1,570.47%
2021 -34,695.90% 195.85%
2020 -11,727.38% 0.00%
2019 0.00% -100.00%
2018 -9,020.69% 0.00%
2017 0.00% -100.00%
2016 -111,411.14% 1,245.37%
2015 -8,281.07% 22.13%
2014 -6,780.72% -74.35%
2013 -26,437.94% 0.00%
2012 0.00% 0.00%
2011 0.00% 0.00%
2010 0.00% 0.00%
2009 0.00% -100.00%
2008 -12,827.49% 212.34%
2007 -4,106.85% 0.00%
同業他社の営業利益率
企業 営業利益率 営業利益率の差
41.30% -100.02%
DK
35.45% -100.02%
US
24.95% -100.01%
US
25.32% -100.01%
BE
25.64% -100.01%
NL
企業の営業利益率とは?
営業利益率は、企業の収益性を評価するための重要な指標です。高い営業利益率は一般的に良いとされており、企業が製品やサービスをその生産コストよりもはるかに高く販売できていることを示します。営業利益率は、企業の利益を売上高で割ることで計算されます。